elvucitabine elvucitabine elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (nrti), developed by achillion pharmaceuticals, inc. for the treatment of hiv infection. elvucitabineclinical dataatc codenoneidentifiers iupac name 4-amino-5-fluoro-1-pyrimidin-2-one cas number181785-84-2 ypubchem cid469717chemspider412628uniim09buf90c0chemblchembl38700 nniaid chemdb060327comptox dashboard (epa)dtxsid20171185 chemical and physical dataformulac9h10fn3o3molar mass227.195 g·mol−13d model (jsmol)interactive image smiles c1c(c(nc(=o)n12c=c(o2)co)n)f inchi inchi=1s/c9h10fn3o3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14h,4h2,(h2,11,12,15)/t5-,7+/m1/s1key:hsbkfspndwwpsl-vdtylamssa-n ny (what is this?) (verify) elvucitabine belongs to a class (group) of hiv drugs called nucleoside reverse transcriptase inhibitors (nrtis). nrtis block an hiv enzyme called reverse transcriptase. (an enzyme is a protein that starts or increases the speed of a chemical reaction). by blocking reverse transcriptase, nrtis prevent hiv from multiplying and can reduce the amount of hiv in the body. elvucitabine is similar in chemical structure to the fda-approved nrtis lamivudine (brand name epivir) and emtricitabine (brand name emtriva). however, in vitro studies have suggested that elvucitabine may work on certain hiv strains against which other nrtis, such as lamivudine and emtricitabine, no longer work. (in vitro studies are studies done in test tubes or other laboratory equipment and not on animals or humans). studies have also suggested that elvucitabine may be effective against hepatitis b virus (hbv). mechanism of action of elvucitabine ; reveals that it acts by inhibiting reverse transcriptase which interferes with generation of dna copies of viral rna. currently, it is in phase ii clinical trials.